BACKGROUND: Serologic response to influenza vaccination declines with age. Few other host factors are known to be associated with serologic response. Our objective was to determine whether obesity and vulnerability independently predicted serologic response to influenza vaccination. METHODS: Adults ≥ 50 years were recruited during the 2008-2009 influenza season. Subjects provided pre- and post-vaccination sera for measuring antibody titers to 2008-2009 vaccine components. Body mass index (BMI) was calculated as weight (kg)/height (m(2)). Data were collected on vulnerability using the vulnerable elders survey (VES13). Logistic regression evaluated the associations between obesity and vulnerability and the serologic response to vaccination (both seroprotection and seroconversion), adjusting for gender, age, comorbidities, pre-vaccination titer, and site. RESULTS: Mean (± standard deviation) age of 415 study subjects was 65 ± 10 years; 40% were obese. Mean BMI was 29 ± 5.6 kg/m(2); mean VES13 was 1.6 ± 1.8. The proportions of subjects who seroconverted and had seroprotective titers were 40% and 49%, respectively, for A/Brisbane/59 (H1N1); 73% and 80% for A/Brisbane/10 (H3N2); and 34% and 94% for B/Florida. Modified VES-13 (score 0-10, with 10 being most vulnerable) was not associated with seroprotection against H1N1 or H3N2, and VES-13 was directly associated with seroconversion to H1N1 but not H3N2 or B. Obesity (BMI ≥ 30 kg/m(2) vs. BMI 18.5-30 kg/m(2)) was not associated with seroprotection for H1N1 or H3N2; obesity was directly associated with seroconversion to H3N2 but not H1N1 or B. Age was inversely associated with seroprotection and seroconversion against H1N1 and with seroconversion to influenza B. CONCLUSION: Based on this sample of older healthy subjects, there were no consistent relationships between VES 13 or obesity and either seroprotection or seroconversion to three influenza vaccine antigens.
BACKGROUND: Serologic response to influenza vaccination declines with age. Few other host factors are known to be associated with serologic response. Our objective was to determine whether obesity and vulnerability independently predicted serologic response to influenza vaccination. METHODS: Adults ≥ 50 years were recruited during the 2008-2009 influenza season. Subjects provided pre- and post-vaccination sera for measuring antibody titers to 2008-2009 vaccine components. Body mass index (BMI) was calculated as weight (kg)/height (m(2)). Data were collected on vulnerability using the vulnerable elders survey (VES13). Logistic regression evaluated the associations between obesity and vulnerability and the serologic response to vaccination (both seroprotection and seroconversion), adjusting for gender, age, comorbidities, pre-vaccination titer, and site. RESULTS: Mean (± standard deviation) age of 415 study subjects was 65 ± 10 years; 40% were obese. Mean BMI was 29 ± 5.6 kg/m(2); mean VES13 was 1.6 ± 1.8. The proportions of subjects who seroconverted and had seroprotective titers were 40% and 49%, respectively, for A/Brisbane/59 (H1N1); 73% and 80% for A/Brisbane/10 (H3N2); and 34% and 94% for B/Florida. Modified VES-13 (score 0-10, with 10 being most vulnerable) was not associated with seroprotection against H1N1 or H3N2, and VES-13 was directly associated with seroconversion to H1N1 but not H3N2 or B. Obesity (BMI ≥ 30 kg/m(2) vs. BMI 18.5-30 kg/m(2)) was not associated with seroprotection for H1N1 or H3N2; obesity was directly associated with seroconversion to H3N2 but not H1N1 or B. Age was inversely associated with seroprotection and seroconversion against H1N1 and with seroconversion to influenza B. CONCLUSION: Based on this sample of older healthy subjects, there were no consistent relationships between VES 13 or obesity and either seroprotection or seroconversion to three influenza vaccine antigens.
Authors: Lisa A Jackson; Michael L Jackson; Jennifer C Nelson; Kathleen M Neuzil; Noel S Weiss Journal: Int J Epidemiol Date: 2005-12-20 Impact factor: 7.196
Authors: Janice K Louie; Meileen Acosta; Michael C Samuel; Robert Schechter; Duc J Vugia; Kathleen Harriman; Bela T Matyas Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: M Provinciali; A Montenovo; G Di Stefano; M Colombo; L Daghetta; M Cairati; C Veroni; R Cassino; F Della Torre; N Fabris Journal: Age Ageing Date: 1998-11 Impact factor: 10.668
Authors: Stephen J Allsup; Alan Shenkin; Margot A Gosney; Stephen Taylor; William Taylor; Margaret Hammond; Maria C Zambon Journal: J Am Geriatr Soc Date: 2004-01 Impact factor: 5.562
Authors: Arash Hassantoufighi; Henry Zhang; Matthew Sandbulte; Jin Gao; Jody Manischewitz; Lisa King; Hana Golding; Timothy M Straight; Maryna C Eichelberger Journal: Vaccine Date: 2009-11-01 Impact factor: 3.641
Authors: Lillian Min; William Yoon; Jeff Mariano; Neil S Wenger; Marc N Elliott; Caren Kamberg; Debra Saliba Journal: J Am Geriatr Soc Date: 2009-09-28 Impact factor: 5.562
Authors: Adrian J Reber; Jin Hyang Kim; Renata Biber; H Keipp Talbot; Laura A Coleman; Tatiana Chirkova; F Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R Griffin; Maria Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara Journal: Open Forum Infect Dis Date: 2015-04-15 Impact factor: 3.835
Authors: Ata Murat Kaynar; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Krissy K Moehling; Michael Susick; Veli Bakalov; Bruce R Pitt; Daniel J Bain; Ted M Ross; Sean G Saul; Mahlon Raymund; Richard K Zimmerman Journal: Hum Vaccin Immunother Date: 2016-01-11 Impact factor: 3.452
Authors: Krissy K Moehling; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Marnie Bertolet; Ted M Ross; Chalise E Carter; Michael Susick; Sean G Saul; A Murat Kaynar; Joyce T Bromberger; Richard K Zimmerman Journal: Hum Vaccin Immunother Date: 2017-12-20 Impact factor: 3.452
Authors: Chyongchiou J Lin; Judith M Martin; Kelly Stefano Cole; Richard K Zimmerman; Michael Susick; Krissy K Moehling; Min Z Levine; Sarah Spencer; Brendan Flannery; Mary Patricia Nowalk Journal: Hum Vaccin Immunother Date: 2017-03-31 Impact factor: 3.452
Authors: Mary S Hayney; Christopher L Coe; Daniel Muller; Chidi N Obasi; Uba Backonja; Tola Ewers; Bruce Barrett Journal: Hum Vaccin Immunother Date: 2013-10-07 Impact factor: 3.452
Authors: Michael A Smit; Hai-Lin Wang; Edward Kim; Noel Barragan; Grace M Aldrovandi; Alvin Nelson El Amin; Laurene Mascola; Pia S Pannaraj Journal: Pediatr Infect Dis J Date: 2016-04 Impact factor: 2.129
Authors: Inna G Ovsyannikova; Sarah J White; Beth R Larrabee; Diane E Grill; Robert M Jacobson; Gregory A Poland Journal: Vaccine Date: 2013-12-18 Impact factor: 3.641